Daily Cardiology Research Analysis
Analyzed 131 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out: a human coronary multi-omics atlas that maps earliest molecular programs of atherogenesis and validates a master regulator (MLXIPL); a catheter-based, intravascular ultrasound–guided piezo-sonodynamic theranostic platform that precisely treats atherosclerotic plaques in vivo; and an AI-enhanced ECG+EHR model that stratifies out-of-hospital cardiac arrest risk with meaningful 2-year incidence separation. Together, they advance pathophysiologic understanding, interventional innovation, and population-level risk prediction.
Research Themes
- Early molecular programs and regulators of human coronary atherogenesis
- Imaging-integrated intravascular theranostics for atherosclerotic plaque
- AI-enabled risk prediction of out-of-hospital cardiac arrest from ECG+EHR
Selected Articles
1. Molecular mechanism leading to human coronary atherosclerosis assessed by proteomic analysis and RNA sequences.
Using 322 human coronary artery samples from young trauma decedents, the authors defined proteomic latent features marking the earliest transition from normal artery to preclinical plaque, including mitochondrial downregulation and neurovascular/immune modulation that precede immune recruitment. Network analyses identified master regulators; MLXIPL was validated in human arterial organoids to modulate LF-linked proteins as predicted.
Impact: This work provides a rare human roadmap of early coronary atherogenesis, linking coordinated proteomic programs to candidate master regulators and validating MLXIPL. It creates actionable targets and datasets for early disease interception.
Clinical Implications: While preclinical, the identified early pathways (mitochondrial bioenergetics decline, neurovascular/immune cues) and regulators (e.g., MLXIPL) could seed biomarker discovery and first-in-human prevention strategies targeting tissue conversion before overt plaque.
Key Findings
- Four proteomic latent features (≈100 signature proteins each) tracked pseudo-time disease progression with FDR < .01.
- Earliest changes included sharp declines in mitochondrial energy proteins and activation of vascular unit/pericyte programs with neurovascular/neuroimmune modulation preceding innate immune recruitment.
- Network mapping identified known and novel master transcriptional regulators; MLXIPL regulated two LFs and was functionally validated in human arterial organoids (P = .0003 and P < .00001).
Methodological Strengths
- Large human tissue biorepository spanning normal-to-preclinical disease with multi-omics integration
- Orthogonal validation using public single-cell datasets and functional arterial organoids
Limitations
- Cross-sectional tissue sampling without prospective clinical outcomes limits causal inference and clinical translation timing
- Pseudo-time and deconvolution rely on computational assumptions; donor heterogeneity (trauma death cohort) may affect generalizability
Future Directions: Translate regulators such as MLXIPL into biomarker assays and target modulation studies; validate early programs in longitudinal human cohorts and interventional models to test disease interception.
BACKGROUND AND AIMS: Atherosclerosis results from cellular and extracellular changes in the arterial wall, preceded by molecular shifts that initiate disease and drive tissue conversion, yet these changes are not yet fully described. More data are needed concerning these early changes in the coronary artery molecular landscape that signify the initiation of atherosclerosis and the subsequent tissue pheno-conversion to atherosclerotic plaque. This report summarizes results from a large biorepository of human coronary artery tissue, applying state-of-the-art omics technology, advanced data analytic methods, and an arterial organoid model system to predict molecular dynamics and identify potential regulatory mechanisms that could interrupt molecular changes that contribute to the earliest stages of disease pathogenesis. The long-term goal of this effort is to identify and develop new therapies to further mitigate the persistently high burden of clinical coronary disease. METHODS: Mass spectrometry-based proteomic analysis and RNA sequencing (RNASeq) were used to analyse proximal coronary arterial samples from young adults who died of trauma with no ante mortem suspicion of coronary disease [n = 322, mean age (range): 34.1 years (15-59); sex: M-239, F-83; race: W-218, B-88, other-16]. Despite the absence of clinical disease, 56% of samples had morphologic evidence of pre-clinical atherosclerosis. Analyses of the proteomic data (n = 1900 proteins) using state-of-the-art dimensionality reduction and deconvolution techniques generated an estimate of molecular disease progression (e.g. pseudo-time) and identified selected proteomic latent features (LFs) (i.e. large groups of co-ordinated proteins) associated with its initiation and progression. Computational genomics, machine learning models, and multi-omic network mapping of these proteomic LFs and associated mRNA gene transcripts suggested potential transcriptional regulators which were subsequently confirmed in publicly available single-cell coronary artery data. The effects of one of the leading regulatory transcription factors (TFs), MLXIPL, predicted to regulate two LFs, were further validated in a human arterial cell organoid model system.
2. Intravascular Ultrasound-Guided Local Theranostics Enables Precise Treatment of Atherosclerotic Plaques.
The authors developed an IVUS-guided, piezoelectric sonodynamic catheter platform leveraging OPN-targeted bismuth nanoparticles to deliver lesion-specific ROS under tunable ultrasound, inducing foam cell apoptosis and plaque regression. Real-time IVUS imaging ensured precise targeting, and preclinical studies showed anti-atherosclerotic efficacy with minimal off-target effects.
Impact: This integrates diagnosis and therapy within a single intravascular platform for deep arterial plaques, overcoming a key translational barrier of SDT and pointing to a clinically feasible coronary application.
Clinical Implications: If translated, this approach could enable precise, image-guided, non-thermal plaque debulking/regression in coronary arteries, potentially complementing or reducing the need for stents in select lesions.
Key Findings
- OPN-targeted, piezoelectric bismuth nanoparticles selectively accumulated in foam cells within plaques.
- IVUS-delivered pulsed ultrasound generated controllable ROS (via PRT/PW modulation) from nanoparticles, triggering foam cell apoptosis and plaque regression.
- Real-time IVUS guidance enabled lesion-specific energy delivery with minimal adverse effects in systematic in vitro and in vivo studies.
Methodological Strengths
- Imaging-treatment integration with quantitative ultrasound parameter control (PRT/PW) enabling mechanistic tuning
- Multi-system validation (cellular, ex vivo/in vivo) demonstrating efficacy and safety
Limitations
- Preclinical stage without human feasibility or long-term safety data, including coronary-specific hemodynamics and microembolization risk
- Target specificity and nanoparticle biodistribution require further characterization for regulatory translation
Future Directions: First-in-human feasibility in peripheral arteries followed by coronary studies, optimization of dosing/ultrasound parameters, and comparative evaluation versus PCI adjuncts.
Although sonodynamic therapy (SDT) has shown promise in reducing atherosclerotic plaque burden, its clinical application remains confined to superficial lesions, as deep-seated plaques such as those in coronary arteries lack precise imaging guidance and lesion-specific energy delivery. Here, we report an intravascular ultrasound (IVUS)-guided SDT strategy that integrates high-resolution imaging and precise treatment within a single catheter system. Osteopontin (OPN)-targeted bismuth-based nanoparticles (BSNPs), endowed with piezoelectricity through defect-induced symmetry breaking, selectively accumulate in foam cells. Pulsed ultrasound emitted by the IVUS catheter triggers BSNPs to generate reactive oxygen species (ROS) through the modulation of pulse-repetition time (PRT) and pulse width (PW), thereby inducing foam cell apoptosis and promoting plaque regression. With IVUS guidance, the SDT process can be visualized in real time, ensuring precise lesion-specific treatment. Systematic in vitro and in vivo studies demonstrate the effective antiatherosclerotic effect with minimal adverse effects. This imaging-integrated piezo-sonodynamic platform establishes a multifunctional catheter-based ultrasound theranostic strategy, providing a precise and clinically translatable approach for treating atherosclerosis.
3. Artificial Intelligence-Enhanced Electrocardiography and Health Records to Predict Cardiac Arrest.
A multimodal AI model combining ECG and EHR features achieved strong discrimination for OHCA (AUROC 0.83) and, in a real-world ECG cohort, flagged about two-thirds of future OHCA cases as high risk. The model separated 2-year cumulative OHCA incidence (2.4% vs 0.5%) under competing-risk adjustment.
Impact: This study demonstrates clinically meaningful, system-level risk stratification for OHCA using routinely collected ECG and EHR data, enabling targeted prevention or monitoring strategies.
Clinical Implications: Health systems could deploy the model for proactive outreach (e.g., wearable defibrillator consideration, electrolyte/medication review, sleep apnea screening), optimizing allocation of preventive resources to those at highest imminent risk.
Key Findings
- ECG+EHR multimodal model achieved AUROC 0.83 and outperformed ECG-only and EHR-only models (pairwise P < 0.05).
- In a real-world ECG cohort, the model flagged 153 of 228 incident OHCA cases as high risk over 2 years (≈67%).
- Two-year cumulative OHCA incidence was 2.4% in high-risk vs 0.5% in low-risk groups under competing-risk adjustment.
Methodological Strengths
- Temporally validated case-control derivation with multimodal feature integration
- Real-world incidence estimation with competing-risk methodology
Limitations
- Observational design with potential confounding and health system–specific practice patterns; external generalizability needs testing
- Clinical utility pathways (e.g., interventions triggered by alerts) and cost-effectiveness not yet evaluated
Future Directions: Prospective impact trials to test alert-driven interventions on OHCA endpoints, external validation across diverse systems, and model fairness auditing.
BACKGROUND: Out-of-hospital cardiac arrest (OHCA) is a public health burden with the majority occurring in the general population for whom there is no firm strategy to predict risk. OBJECTIVES: The authors evaluated whether artificial intelligence enhanced electrocardiography (ECG) and clinical information from electronic health records (EHRs) can stratify risk of OHCA in the general population. METHODS: We use a case-control study design (matching on age and sex), to derive and temporally validate models to predict OHCA. To evaluate the potential use case of models in a real-world context, we evaluated the 2-year cumulative incidence of OHCA in individuals undergoing ECG in a health care system, while accounting for the competing risk of non-OHCA mortality. RESULTS: In the temporal validation cohort, discrimination of OHCA was highest for the multimodal ECG + EHR model (area under the receiver operating characteristic curve: 0.83; area under the precision recall curve: 0.44) followed by the EHR-only model and the ECG-only model (Bonferroni adjusted P for all pairwise comparisons <0.05). In the real-world cohort of individuals undergoing ECG, the EHR + ECG model flagged two-thirds (153 of 228) of those with incident OHCA over a 2-year period as high-risk. Using the ECG + EHR model, the 2-year cumulative incidence of OHCA was 2.4% (95% CI: 2.0%-2.8%) in individuals identified as high-risk compared with 0.5% (95% CI: 0.3%-0.8%) in individuals designated as low risk. CONCLUSIONS: In a large U.S. health care system, artificial intelligence-enhanced ECG and EHR data effectively discriminated individuals at risk of OHCA and identified those at clinically relevant risk of incident OHCA over a 2-year period.